Amicogen Inc (092040) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amicogen Inc (092040) has a cash flow conversion efficiency ratio of -0.027x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.58 Billion ≈ $-2.43 Million USD) by net assets (₩133.35 Billion ≈ $90.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Amicogen Inc market capitalisation for the company's overall valuation and market capitalisation.
Amicogen Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Amicogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amicogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicogen Inc ranked by their cash flow conversion efficiency. Explore 092040 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Circle8 Group, Inc.
NASDAQ:CIRC
|
-0.181x |
|
Theragen Etex Co.Ltd
KQ:066700
|
0.020x |
|
Xander International
TWO:6118
|
-0.158x |
|
S P V I Public Company Limited
BK:SPVI
|
0.102x |
|
RFTech Co. Ltd
KQ:061040
|
-0.045x |
|
Krynica Vitamin SA
WAR:KVT
|
0.004x |
|
Dongyang Expre
KO:084670
|
0.059x |
|
BANXA HOLDINGS INC.
F:AC00
|
N/A |
Annual Cash Flow Conversion Efficiency for Amicogen Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Amicogen Inc from 2014 to 2025. View Amicogen Inc (092040) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩95.86 Billion ≈ $64.96 Million |
₩-24.42 Billion ≈ $-16.55 Million |
-0.255x | -134.05% |
| 2024-12-31 | ₩122.50 Billion ≈ $83.01 Million |
₩-13.34 Billion ≈ $-9.04 Million |
-0.109x | -375.82% |
| 2023-12-31 | ₩218.97 Billion ≈ $148.40 Million |
₩8.64 Billion ≈ $5.86 Million |
0.039x | +123.21% |
| 2022-12-31 | ₩131.80 Billion ≈ $89.32 Million |
₩-22.41 Billion ≈ $-15.19 Million |
-0.170x | -492.13% |
| 2021-12-31 | ₩186.16 Billion ≈ $126.16 Million |
₩8.07 Billion ≈ $5.47 Million |
0.043x | -25.19% |
| 2020-12-31 | ₩152.94 Billion ≈ $103.65 Million |
₩8.87 Billion ≈ $6.01 Million |
0.058x | -19.24% |
| 2019-12-31 | ₩122.05 Billion ≈ $82.71 Million |
₩8.76 Billion ≈ $5.94 Million |
0.072x | +221.69% |
| 2018-12-31 | ₩127.28 Billion ≈ $86.26 Million |
₩2.84 Billion ≈ $1.92 Million |
0.022x | -83.25% |
| 2017-12-31 | ₩89.19 Billion ≈ $60.44 Million |
₩11.88 Billion ≈ $8.05 Million |
0.133x | -3.68% |
| 2016-12-31 | ₩81.54 Billion ≈ $55.26 Million |
₩11.28 Billion ≈ $7.64 Million |
0.138x | -8.00% |
| 2015-12-31 | ₩82.10 Billion ≈ $55.64 Million |
₩12.34 Billion ≈ $8.36 Million |
0.150x | +69.90% |
| 2014-12-31 | ₩50.02 Billion ≈ $33.90 Million |
₩4.43 Billion ≈ $3.00 Million |
0.088x | -- |
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more